Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Dcc-2701
1. 1345847-93-9
2. Dcc-2701
3. Dp-5164
4. Altiratinib [usan]
5. Altiratinib (usan)
6. 1,1-cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-
7. 1,1-cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)-
8. N-(4-((2-((cyclopropylcarbonyl)amino)pyridin-4-yl)oxy)-2,5-difluorophenyi)-n-(4- Fluorophenyl)cyclopropane-1,1-dicarboxamide
9. T678746713
10. 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
11. N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
12. N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
13. Unii-t678746713
14. Altiratinib;dcc2701
15. Altiratinib [inn]
16. Altiratinib(dcc-2701)
17. Altiratinib [who-dd]
18. Schembl139906
19. Gtpl9174
20. Chembl3545365
21. Dcc-270
22. Dcc2701
23. Ex-a902
24. Bcp15682
25. Hy-b0791
26. Bdbm50193395
27. Mfcd28900672
28. Nsc784590
29. S6412
30. Akos026750329
31. Zinc113198271
32. Cs-3944
33. Nsc-784590
34. Sb18876
35. Ncgc00480913-04
36. Ac-35383
37. N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
38. Ft-0700171
39. A14387
40. D10862
41. F11464
42. A887875
43. J-690136
44. Q27074416
45. 1,1-cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n-(4-fluorophenyl)-
46. 4-{5-[(e)-2-{4-(2-chlorophenyl)-5-[5-(methylsulfonyl)-2-pyridinyl]-4h-1,2,4-triazol-3-yl}vinyl]-1,3,4-oxadiazol-2-yl}benzonitrile
47. A9i
48. N-1'-[4-[2-(cyclopropylcarbonylamino)pyridin-4-yl]oxy-2,5-bis(fluoranyl)phenyl]-n-1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
Molecular Weight | 510.5 g/mol |
---|---|
Molecular Formula | C26H21F3N4O4 |
XLogP3 | 4.3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 8 |
Exact Mass | 510.15148965 g/mol |
Monoisotopic Mass | 510.15148965 g/mol |
Topological Polar Surface Area | 109 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 863 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
61
PharmaCompass offers a list of Altiratinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Altiratinib manufacturer or Altiratinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Altiratinib manufacturer or Altiratinib supplier.
PharmaCompass also assists you with knowing the Altiratinib API Price utilized in the formulation of products. Altiratinib API Price is not always fixed or binding as the Altiratinib Price is obtained through a variety of data sources. The Altiratinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Altiratinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Altiratinib, including repackagers and relabelers. The FDA regulates Altiratinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Altiratinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Altiratinib supplier is an individual or a company that provides Altiratinib active pharmaceutical ingredient (API) or Altiratinib finished formulations upon request. The Altiratinib suppliers may include Altiratinib API manufacturers, exporters, distributors and traders.
Altiratinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Altiratinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Altiratinib GMP manufacturer or Altiratinib GMP API supplier for your needs.
A Altiratinib CoA (Certificate of Analysis) is a formal document that attests to Altiratinib's compliance with Altiratinib specifications and serves as a tool for batch-level quality control.
Altiratinib CoA mostly includes findings from lab analyses of a specific batch. For each Altiratinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Altiratinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Altiratinib EP), Altiratinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Altiratinib USP).